Detail akcie ACADIA Pharm online

Business Summary: Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.
Financial Summary: BRIEF: For the three months ended 31 March 2025, ACADIA Pharmaceuticals Inc revenues increased 19% to $244.3M. Net income increased 15% to $19M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was partially offset by General And Administrative Expencess increase of 22% to $118.8M (expense), Other Research and development increase of 35% to $74.8M (expense).